Medicure Q2 2023 Earnings Report $0.60 0.00 (0.00%) As of 01/7/2025 Earnings History Medicure EPS ResultsActual EPS$0.01Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AMedicure Revenue ResultsActual Revenue$4.46 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMedicure Announcement DetailsQuarterQ2 2023Date7/28/2023TimeN/AConference Call ResourcesMCUJF Earnings History Get paid to hold crypto? (Ad)Man Who Recommended Bitcoin at $600 – Reveals: “Crypto Royalties” My #1 Crypto Play for 2025 and Beyond… It’s from a little-known asset I call “Crypto Royalties.”Go here and I’ll show you how. Medicure Earnings HeadlinesMedicure Sees Revenue Growth in Q3 2024November 25, 2024 | tipranks.comMedicure, Inc.: Medicure Announces Positive Settlement of Product Development and Supply ContractsOctober 25, 2024 | finanznachrichten.deGet paid to hold crypto? Man Who Recommended Bitcoin at $600 – Reveals: “Crypto Royalties” My #1 Crypto Play for 2025 and Beyond… It’s from a little-known asset I call “Crypto Royalties.”January 8, 2025 | Centurion Publishing (Ad)Medicure Second Quarter 2024 Earnings: CA$0.12 loss per share (vs CA$0.024 profit in 2Q 2023)August 18, 2024 | finance.yahoo.comMedicure, Inc.: Medicure Announces Closing of Asset Purchase Agreement with Canam Bioresearch for Acquisition of Intellectual PropertyAugust 15, 2024 | finanznachrichten.deMedicure Reports Financial Results for Quarter Ended March 31, 2024 and Annual General Meeting Director Election ResultsMay 28, 2024 | finance.yahoo.comSee More Medicure Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Medicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medicure and other key companies, straight to your email. Email Address About MedicureMedicure (OTCMKTS:MCUJF), a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.View Medicure ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles S&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Upcoming Earnings Schlumberger (1/17/2025)Procter & Gamble (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
